Premium
Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients
Author(s) -
CorreiaSilva JF,
BrunaRomero O,
Resende RG,
Miranda LPM,
Oliveira FE,
Costa FO,
Xavier SG,
FigueiredoNeves SP,
Almeida HC,
Bittencourt H,
Gomez RS
Publication year - 2010
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.2009.01637.x
Subject(s) - saliva , human cytomegalovirus , hematopoietic stem cell transplantation , immunology , stem cell , medicine , transplantation , hematopoietic stem cell , real time polymerase chain reaction , viral load , whole blood , cytomegalovirus , herpesviridae , haematopoiesis , virology , biology , virus , viral disease , gene , biochemistry , genetics
Oral Diseases (2010) 16 , 210–216 Objective: The purpose of this study was to investigate the use of saliva for the identification of human cytomegalovirus (HCMV) in allogeneic hematopoietic stem cell transplant patients by real time PCR compared with blood. Materials and methods: Saliva and blood samples were sampled weekly in 30 allogeneic hematopoietic stem cell transplant patients until 100 days after transplant. Total genomic DNA, extracted from saliva and whole‐blood samples, was used for HCMV real time PCR. Nonparametric tests were performed, and P value ≤0.05 was considered statistically significant. Results: Human cytomegalovirus DNA load in saliva showed a high correlation with viral DNA in the blood ( R = 0.858; P < 0.0001). Blood DNA levels also correlated with HCMV antigenemia ( R = 0.773; P < 0.0001). The HCMV levels in saliva ( P = 0.015) and blood ( P = 0.008) showed higher levels at the beginning of antiviral treatment, with clear reduction after this period. Saliva showed earlier HCMV reactivation than blood detected by real time PCR and antigenemia assay in 11 out of 22 subjects. Conclusions: This study shows that the real time PCR test could be useful to identify HCMV DNA in saliva and to monitor patients at risk of cytomegalovirus disease after allogeneic hematopoietic stem cell transplant. However, further studies are necessary to confirm this data.